PIN

Aviat Networks Announces Fiscal 2024 Third Quarter and Nine Month Financial Results

Retrieved on: 
Wednesday, May 1, 2024
International, PIN, Aviat Networks, Depreciation, Webcast, Corporate development, Acquisition, Adjustment, Telephone, GAAP, Growth, Operation, Interest, Aviat

AUSTIN, Texas, May 1, 2024 /PRNewswire/ -- Aviat Networks, Inc. ("Aviat Networks," "Aviat," or the "Company"), (Nasdaq: AVNW), the leading expert in wireless transport and access solutions, today reported financial results for its fiscal 2024 third quarter ended March 29, 2024.

Key Points: 
  • Total Revenue of $111.6 million; Up 33.7% Year-Over-Year
    Adjusted EBITDA of $12.0 million; Up 11.1% Year-Over-Year
    Cash from Operations of $15.3 million in current quarter, $22.2 million year-to-date
    AUSTIN, Texas, May 1, 2024 /PRNewswire/ -- Aviat Networks, Inc. ("Aviat Networks," "Aviat," or the "Company"), (Nasdaq: AVNW), the leading expert in wireless transport and access solutions, today reported financial results for its fiscal 2024 third quarter ended March 29, 2024.
  • Fiscal 2024 Third Quarter and Nine Months Ended March 29, 2024
    The Company reported total revenues of $111.6 million for its fiscal 2024 third quarter, compared to $83.5 million in the fiscal 2023 third quarter, an increase of $28.1 million or 33.7%.
  • In the fiscal 2024 third quarter, the Company reported GAAP gross margin of 32.7% and non-GAAP gross margin of 35.2%.
  • The Company is updating its fiscal 2024 full year guidance as follows:
    Aviat Networks will host a conference call at 5:00 p.m. Eastern Time (ET) today, May 1, 2024, to discuss its financial and operational results for the fiscal 2024 third quarter ended March 29, 2024.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
Tuesday, April 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

111 to Announce First Quarter 2024 Unaudited Financial Results on May 23, 2024 - Conference Call to Follow

Retrieved on: 
Tuesday, April 30, 2024
Patient, Password, Calendar, Medicine, PIN, Internet service provider

111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day).

Key Points: 
  • 111's management team will host an earnings conference call at 7:30 AM U.S. Eastern Time on Thursday, May 23, 2024 (7:30 PM Beijing Time on the same day).
  • Details for the conference call are as follows:
    All participants must use the link provided above to complete the online registration process in advance of the conference call.
  • Upon registering, each participant will then be provided with the dial in number, the Passcode, and your unique access PIN.
  • A telephone replay of the call will be available after the conclusion of the conference call until May 30, 2024.

Novelis to Host Fourth Quarter and Full Fiscal Year 2024 Earnings Conference Call on May 6

Retrieved on: 
Monday, April 29, 2024
EDT, Telephone, Webcast, Novelis, PIN, IST

ATLANTA, April 29, 2024 /PRNewswire/ -- Novelis Inc. will report its earnings for the fourth quarter and full fiscal year 2024 on Monday, May 6, 2024.

Key Points: 
  • ATLANTA, April 29, 2024 /PRNewswire/ -- Novelis Inc. will report its earnings for the fourth quarter and full fiscal year 2024 on Monday, May 6, 2024.
  • Following the release, Steve Fisher, president and chief executive officer, and Dev Ahuja, chief financial officer, will discuss the results via a live conference call for investors at 7:00 a.m. EDT / 4:30 p.m. IST the same day.
  • The conference call will also be webcast live via the Novelis website, with presentation materials available online at https://investors.novelis.com/ .
  • The webcast can be accessed live at: https://links.ccwebcast.com/?EventId=NOV060524
    To participate by telephone, participants are requested to register at: https://services.choruscall.in/DiamondPassRegistration/register?confirma...
    Upon registering you will receive the dial-in info and a unique PIN to join the call as well as an email confirmation with the details.

JinkoSolar Announces First Quarter 2024 Financial Results

Retrieved on: 
Monday, April 29, 2024
Sale, Topcon, Cell, Investment, PIN, Economics, IEA, Research, Electricity, Conference, Growth, AAA, Development, Risk management, Wind, ADS, RMB, Pressure, Posterior predictive distribution, RSVP, JinkoSolar, Calendar, The Company, JKS, Note, International Energy Agency, Renewable energy

SHANGRAO, China, April 29, 2024 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced its unaudited financial results for the first quarter ended March 31, 2024.

Key Points: 
  • SHANGRAO, China, April 29, 2024 /PRNewswire/ -- JinkoSolar Holding Co., Ltd. ("JinkoSolar" or the "Company") (NYSE: JKS), one of the largest and most innovative solar module manufacturers in the world, today announced its unaudited financial results for the first quarter ended March 31, 2024.
  • Gross profit in the first quarter of 2024 was RMB2.74 billion (US$378.8 million), compared with RMB4.09 billion in the fourth quarter of 2023 and RMB4.04 billion in the first quarter of 2023.
  • Gross margin was 11.9% in the first quarter of 2024, compared with 12.5% in the fourth quarter of 2023 and 17.3% in the first quarter of 2023.
  • It will automatically direct you to the registration page of "JinkoSolar First Quarter 2024 Earnings Conference Call", where you may fill in your details for RSVP.

EQS-News: STRATEC POSTS RESULTS FOR FIRST QUARTER OF 2024

Retrieved on: 
Friday, May 3, 2024
Annual, Investment, PIN, Management, Forecasting, Development, COVID-19, Magazine, AGM, Growth

Adjusted EBIT stood at € 3.1 million in the first quarter of 2024, compared with € 3.8 million in the previous year’s quarter.

Key Points: 
  • Adjusted EBIT stood at € 3.1 million in the first quarter of 2024, compared with € 3.8 million in the previous year’s quarter.
  • In view of this and given that developments in the first quarter were consistent with expectations, STRATEC can confirm its financial guidance for 2024.
  • In the first quarter of 2024, STRATEC pressed ahead once again with numerous developments and projects and concluded new agreements for new cooperations.
  • To mark the publication of the results for the first quarter of 2024, STRATEC will be holding a conference call in English at 2.00 p.m. (CEST) today, Friday, April 26, 2024.

EQS-News: Evotec SE to announce results for fiscal year 2023 on 24 April 2024

Retrieved on: 
Friday, May 3, 2024
MDAX, Frankfurt Stock Exchange, EDT, Webcast, EVO, BST, PIN, Broadcasting

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2023 on Wednesday, 24 April 2024.
  • The Company is going to hold a conference call to discuss the results as well as provide an update on its performance.
  • Time: 3.00 pm CEST (02.00 pm BST, 09.00 am EDT)
    To join the audio webcast and to access the presentation slides, please register via this link .
  • You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call.

EQS-News: Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth

Retrieved on: 
Friday, May 3, 2024
Science, Annual general meeting, EDT, Investment, PIN, Paris Agreement, EVT201, HR, Partnership, Growth, Targets, Insomnia, Webcast, Janssen, Evotec, Novartis, Science Based Targets initiative, Just, Supervisory board, Interim, BMS, Medicine, Capsule

Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.

Key Points: 
  • Just – Evotec Biologics contributed € 108.4 m to the total group revenue compared to € 51.3 m in 2022, reflecting a 111% growth.
  • In March 2023, BMS and Evotec extended and expanded the neurodegeneration partnership, originally signed in 2016, for an additional eight years.
  • Evotec plans to update the market on its mid-term forecast with the release of its H1 2024 results in August 2024.
  • As part of this priority reset and in line with market developments, Evotec will simplify its reporting to Shared R&D and Just – Evotec Biologics starting Q1 2024.

EQS-News: Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Retrieved on: 
Friday, May 3, 2024
Pharmacy, PIN, EUR, Plasma protein binding, Prescription, Smartphone, QR, Patient, Redcare, Sevenum, Pharmaceutical industry

Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Key Points: 
  • Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
  • Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.
  • Today, Redcare Pharmacy has successfully obtained the provider approval by the gematik for its eHealth-CardLink solution, while its development partner eHealth Experts simultaneously received the product approval.
  • Customers of online pharmacies will still be able to use the gematik app or scan the QR code on the printed prescription.

The Tile Shop to Host First Quarter 2024 Earnings Conference Call

Retrieved on: 
Thursday, May 2, 2024
PIN, News, Security (finance), Webcast, Regulation Fair Disclosure, Regulation, Disclosure, Financial adviser

The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern Time on Thursday, May 9, 2024.

Key Points: 
  • The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern Time on Thursday, May 9, 2024.
  • The call will be hosted by Cabell Lolmaugh, Chief Executive Officer, Mark Davis, Chief Financial Officer, and Ken Cooper, Investor Relations.
  • A webcast of the call can be accessed by visiting the Company’s Investor Relations page at www.tileshop.com .
  • A webcast replay of the call will be available on the Company’s Investor Relations page at www.tileshop.com .